Soligenix, Inc. · NASDAQ:SNGX
Soligenix — Investor Presentation (May 2016)
25 slides from Soligenix's investor presentation, May 2016
Slide 1: Rising to the Challenges of Rare Disease Treatment
… Rising to the Challenges of Rare Disease Treatment OTC QB: SNGX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products a
Slide 3: Company Highlights
Company Highlights Diversified product portfolio in advanced development, targeting rare disease indications in inflammation, oncology and biodefense with $200M+ markets worldwide o Phase 3 clinical program for the treatment of cutaneous T-cell lymphoma (SGX301) - Orphan drug and fast track design
Slide 4: Rare Disease Pipeline
Rare Disease Pipeline BioTherapeutics Product Candidates Preclinical Phase 1 Phase 2 Phase 3 Market SGX301 ORPHAN & FAST TRACK DESIGNATIONS Ph. 3 data 2H 2016* Cutaneous T-Cell Lymphoma (CTCL) SGX203 Ph. 3 data 2H 2017* ORPHAN & FAST TRACK DESIGNATIONS Pediatric Crohn’s Disease** SGX942 FAST TRACK D
Slide 5: Multiple Potential Value Drivers
Multiple Potential Value Drivers 2015 2016 2017 SGX301 Ph. 3 study 2H: Ph. 3 data 2H: NDA initiated in CTCL in CTCL submission CTCL SGX942 Positive Ph. 2 data 2H: FDA clearance 1H: Ph. 2/3 start in in Oral Mucositis Ph. 2/3 protocol Oral Mucositis FDA clearance 1H: Ph. 3 start in 2H: Ph. 3 data in S
Slide 6: Significant WW Market Potential
Significant WW Market Potential $500+ Assumptions(1) 500 $450 Oral Mucositis in Head and Neck Cancer 450 90,000 Patients US 90,000 Patients EU 400 Cutaneous T-Cell Lymphoma 20,000 Patients US 350 $ Millions $300 20,000 Patients EU 300 Pediatric Crohn’s Disease 80,000 Patients US $250 250 80,000 Pati
Slide 7: Experienced Management and Board of Directors
Experienced Management and Board of Directors • 26 years of experience • Discovery Laboratories (COO) Christopher J. Keith Brownlie, • 35 years of experience Schaber, PhD • Acute Therapeutics (Co-Founder) CPA • Ohmeda Pharmaceuticals • Ernst & Young President & CEO • The Liposome Company • Wyeth Aye
Slide 8: BioTherapeutics
BioTherapeutics Targeted Approach to Treating Oncology & Inflammation 8
Slide 9: BioTherapeutics Business Segment
BioTherapeutics Business Segment Commercial targets – unmet medical needs in oncology and inflammation SGX301 Cutaneous T-Cell (Synthetic Hypericin) Lymphoma Oncology and Oral Mucositis in SGX942 Oncology Head and Neck (Dusquetide) Cancer Supportive Care Soligenix SGX201 Acute Radiation BioTherapeut
Slide 10: Cutaneous T-Cell Lymphoma – Disease Overview
Cutaneous T-Cell Lymphoma – Disease Overview Atypical T-cells in dermis Cutaneous T-cell lymphoma (CTCL) o Rare class of Non-Hodgkin's Lymphoma (NHL) o Malignant T-cells migrate to the skin o Cancer forms patches or lesions CTCL affects over 40,000 NHL patients worldwide; currently no cure Two
Slide 11: SGX301 – Synthetic Hypericin
SGX301 – Synthetic Hypericin SGX301 is a first-in-class, topical drug applied to CTCL skin lesions followed by activation with safe, visible, fluorescent light to kill malignant T-cells Affects over 40,000 patients annually worldwide No approved front-line therapy for early stage (I-IIA) CTCL (~
Slide 12: SGX301 – Phase 2 Response Rate
SGX301 – Phase 2 Response Rate CTCL Patch Hypericin Therapy CTCL Patch Pre-Therapy Using Visible Light Post -Therapy Summary of CTCL Lesion Responses to Synthetic Hypericin Ointment Following Six Weeks of Treatment Responders/Total Percent Responders Hypericin Responders 7/12 58.3% Placebo Responder
Slide 13: Oral Mucositis – Disease Overview
Oral Mucositis – Disease Overview Inflammation causes worsening damage Ref: S. Sonis 2004 Oral mucositis (OM) Secondary infection o Multi-factorial disease linked to a dysregulation of the innate immune system OM affects over 180,000 head and neck (H&N) cancer patients worldwide Debilitating s
Slide 14: SGX942 – Innate Defense Regulator
SGX942 – Innate Defense Regulator SGX942 (dusquetide) is a first-in-class, injectable drug, called an Innate Defense Regulator (IDR), that modulates the body’s innate immune system to reduce inflammation OM affects over 180,000 H&N cancer patients worldwide No approved drug for OM in H&N cancer;
Slide 15: SGX942 – Preliminary Oral Mucositis Results
SGX942 – Preliminary Oral Mucositis Results Phase 2 exploratory clinical study o Enrolled H&N cancer patients receiving at least 55 Gy radiation and either weekly (30-40mg/m2) or every 3rd week (80-100mg/m2) chemotherapy o Dose escalating: Placebo, 1.5, 3.0 and 6.0 mg/kg administered twice weekly
Slide 16: SGX942 – Preliminary Oral Mucositis Results
SGX942 – Preliminary Oral Mucositis Results Clinically Meaningful Results o 50% decrease in duration of severe OM overall with 67% decrease in patients receiving aggressive chemotherapy (80-100 mg/m2) Consistent with decreased incidence and delay in mean onset of severe OM o Increased incidence
Slide 17: Pediatric Crohn's Disease – Disease Overview
Pediatric Crohn’s Disease – Disease Overview Normal mucosa under endoscopy Pediatric Crohn’s disease o Chronic inflammatory disorder of the gastrointestinal (GI) tract o Diarrhea, rectal bleeding and abdominal pain Resulting in growth failure, malnutrition, pubertal delay and bone demineralizati
Slide 18: SGX203 – Beclomethasone Dipropionate
SGX203 – Beclomethasone Dipropionate SGX203 is a proprietary oral formulation of immediate and delayed release beclomethasone 17,21-dipropionate (BDP) tablets to treat GI inflammation with less toxicity than the current standard systemic steroid therapy 160,000 children/adolescents with Crohn’s di
Slide 19: Vaccine/BioDefense
Vaccine/BioDefense Addressing Critical Concerns for Industry and Government 19
Slide 20: Vaccine/BioDefense Business Segment
Vaccine/BioDefense Business Segment Infectious Disease: HPV and Ebola Vaccines ThermoVax® Vaccine Heat Stabilization Platform BioDefense: RiVaxTM Ricin Vaccine Soligenix Vaccine / BioDefense Segment* OrbeShield® Gastrointestinal Acute Radiation Syndrome (Oral BDP Therapeutic) (GI ARS) * Funded by Go
Slide 21: ThermoVax – Vaccine Thermostability Platform
ThermoVax® – Vaccine Thermostability Platform % Im m u n o g e n ic ity ThermoVax® is a proprietary 100 freeze-drying process that o 4 0 C T h e rm o V a x Positive results: enables vaccines to be stored 50 o 4 0 C O r ig in a l o Ricin vaccine without refrigeration o Anthrax vaccine o HPV vaccine D
Slide 22: RiVax – Ricin Toxin Vaccine
RiVaxTM – Ricin Toxin Vaccine 100 Heat-stable ricin vaccine provided * L a te d e a th n o t d ire c tly 100% protection in a non-human % S u r v iv a l 75 a ttrib u te d to ric in in to x ic a tio n primate aerosol challenge model V a c c in e (N = 1 2 ) (right) 50 S h a m (N = 6 ) Demonstrated saf
Slide 23: OrbeShield for GI Acute Radiation Syndrome
OrbeShield® for GI Acute Radiation Syndrome Two-tablet BDP system also 100 efficacious in animal models of % S u r v iv a l 75 gastrointestinal acute radiation syndrome (GI ARS) 50 B D P (N = 6 ) Preliminary proof of concept data 25 P la c e b o (N = 4 ) in canine model of GI ARS (right) p < 0 .0 5
Slide 24: Investment Highlights
Investment Highlights Diversified product portfolio in advanced development, targeting rare disease indications in inflammation, oncology and biodefense with $200M+ markets worldwide o Phase 3 clinical program for the treatment of cutaneous T-cell lymphoma (SGX301) - Orphan drug and fast track des
Slide 25: THANK YOU
Rising to the Challenges of Rare Disease Treatment THANK YOU www.soligenix.com